Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
The article was authored by scientists from the Mayo Clinic Cancer Center, the Hollings Cancer Center at the Medical University of South Carolina and Apogee Biotechnology Corporation RedHill...
-
TEL-AVIV, Israel, March 09, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the...
-
The RHB-105 first Phase III Clinical Study Report demonstrates the efficacy and safety of RHB-105 in eradication of H. pylori infection, supports the potential superior efficacy of RHB-105 over...
-
RedHill’s advanced pipeline includes three Phase III programs, several Phase II programs and additional early-stage programs.RedHill maintains a strong and debt-free balance sheet, allowing the...
-
TEL-AVIV, Israel, Feb. 25, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development...
-
Key Highlights Include: RedHill maintains a strong and debt-free balance sheet with approximately $58 million in cash and cash equivalents at the end of 2015, allowing the Company to continue to...
-
The new U.S. patent is expected to be valid until 2034, once granted RedHill and its co-development partner, IntelGenx Corp., recently announced the national approval of RIZAPORT™ in Germany...
-
TEL-AVIV, Israel, Feb. 18, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), an Israeli biopharmaceutical company primarily focused on the...
-
Dr. Almenoff previously served as President, Principal Executive Officer and Chief Medical Officer of Furiex Pharmaceuticals (now Actavis plc)Ms. Stevens previously served as Chief Corporate...
-
RedHill recently concluded a successful first-in-man pharmacokinetic (PK) study with BEKINDA™ 12 mg (RHB-102) proprietary formulation, to support the planned Phase II study for the treatment of...